Press parameter Application Number (Jone Variance) Application Number (Jone Variance) Image: Commerce Com	Effective on 12/08/2004.				Complete if Known					
FEE TRANSMITTAL for FY 2005 Find Date November 21, 2005 □ Applicant claims small entity status. See 37 CFR 1.27 Examiner Name Not Yet Assigned TOTAL AMOUNT OF PAYMENT (\$) 1.000.00 Attoms y Dockel No. CARP0001-112 METHOD OF PAYMENT (\$) 1.000.00 Attoms y Dockel No. CARP0001-112 METHOD OF PAYMENT (check all that apply) □ Check □ Credit Card □ Money Order □ None □ Other (please identify) :	FEE TRANSMITTAL			Applic	Application Number Not Yet Assigned					
for FY 2005 First Named Inventor John R. Adatr et al. □ Applicant claims small entity status. See 37 CFR 1.27 Examiner Name Not Yet Assigned TOTAL AMOUNT OF PAYMENT (\$) 1,000.00 Art Unit Not Yet Assigned □ OTAL AMOUNT OF PAYMENT (\$) 1,000.00 Art Unit Not Yet Assigned □ Check Credit Card Money Order None Other (please identify) : □ Deposit Account Number 50-1275 Deposit Account Name: Cozen O'Connor, P.C. For the above-identify deposit account, the Director is hereby subtricated to: (check all that apply) □ Charge fee(s) Indicated below □ Charge fee(s) indicated below □ Other 70 CFR 1.16 and 1.17 □ Charge fee(s) indicated below, except for the filling □ Andro 70 CFR 1.16 and 1.17 □ Charge fee(s) indicated below, except for the filling □ Andro 70 CFR 1.16 and 1.17 □ Charge fee(s) indicated below, except for the filling □ Andro 70 CFR 1.16 and 1.17 □ Charge fee(s) indicated below □ Charge fee(s) indicated below, except for the filling □ Andro 70 CFR 1.16 and 1.17 □ Charge fee(s) indicated below, except for the filling □ Charge fee(s) indicated below □ Andro 70 CFR 1.10 O □ Charge fee(s) □ Charge fee(s)				Filing						
□ Applicant claims small entity status. See 37 CFR 1.27 Examiner Name Not Yet Assigned TOTAL AMOUNT OF PAYMENT (5) 1.000.00 Attuin: Not Yet Assigned ■ CTAL AMOUNT OF PAYMENT (5) 1.000.00 Attuin: Not Yet Assigned ■ CTAL AMOUNT OF PAYMENT (5) 1.000.00 Attuin: Not Yet Assigned ■ CTAL AMOUNT OF PAYMENT (5) 1.000.00 Attomay Docket No. CARP0001-112 ■ CTAL AMOUNT OF PAYMENT (5) 1.000.00 Attomay Docket No. CARP0001-112 ■ Check Credit Card Money Order None Other (please identify) : ■ Deposit Account Deposit Account Number: 50-1275 Deposit Account Name: Cozen O'Connor, P.C. For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge 6ets) indicated below Charge 6ets) indicated below, except for the filling to the above-identify is indicated below, except for the filling to the above-identify is indicated below. Scrept 1178 ■ Charge 6ets) indicated below ■ Charge 6ets) indicated below. Except 1188 ■ Charge 6ets) indicated below ■ Charge 6ets) indicated below. Except 1188 ■ Charge 6ets) indicated below ■ Charge 6ets) indicated below. Except 1188 ■ Charge 6ets) indicated below	for FY 2005				First Named Inventor John R. Adair et al.					
TOTAL AMOUNT OF PAYMENT (\$) 1,000.00 Art Unit Not Yet Assigned Attorney Docket No. CARP0001-112 METHOD OF PAYMENT (check all that apply) Check Credit Card Money Order None Other (please identify) :	Applicant claims small entity status. See 37 CFR 1.27				iner Name	Not Yet Assigned				
TOTAL AMOUNT OF PAYMENT (\$) 1,000.00 Attorney Docket No. CARP8081-112 METHOD OF PAYMENT (check all that apply)					nit	Not Yet Assigned				
METHOD OF PAYMENT (check all that apply) □ Check □ Credit Card □ Money Order □ None □ Other (please identify) :	TOTAL AMOUNT OF PAYMENT		(\$) 1,000.00	Attorn	Attorney Docket No. CARP0001-112					
□ Check □ Credit Card Money Order None Other (please identify) :	METHOD OF PAYMENT	(check a	II that apply)							
☑ Deposit Account Number: 50-1275 Deposit Account Name: Cozen O'Connor, P.C. For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) ☑ Charge fee(s) indicated below □ Charge fee(s) indicated below, except for the filling ☑ Charge fee(s) indicated below □ Charge fee(s) indicated below, except for the filling ☑ Charge fee(s) indicated below, except for the filling ☑ Charge fee(s) indicated below □ Charge fee(s) indicated below, except for the filling ☑ Charge fee(s) indicated below, except for the filling WRNING: information on this form may become public. Credit eard information aboutd not be included on this form. Provide credit eard information and authorization on PTO-2338. FEE CALCULATION 1. BASIC FILING, SEARCH, AND EXAMINATION FEES Filining Fee(s) Fee(Check Credit Card	D Mo	ney Order 🗍 None	1 Other	(please identif	ÿ):				
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	Deposit Account Depos	sit Accour	t Number: 50-1275	- 1.5	Deposit Acc	ount Name: Coz	en O'Connor, P	.C.		
Index of the adverted matrix of the object is the object is the object is the object is adverted below, except for the filling is the object is the obje	Ear the above idea	tified den	sit account the Directo	r is horsh	- authorized to:	(check all that a	nolvi			
∑ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filling ∑ Charge any additional fee(s) or underpayments of fee(s) ∑ Credit any overpayments Under 37 CFR 1.16 and 1.17 WARNING: Information or this form may become public. Credit card information should not be included on this form. Provide credit card information adultorization or this form may become public. Credit card information adultorization or the TPO 2028. FEE CALCULATION 1. BASIC FILING, SEARCH, AND EXAMINATION FEES FILING FEES Standl Entity Small Entity Small Entity Application Type Fee(S) Fee(S) Fee(S) Plant 200 100 300 150 500 250 600 200 100 200 100 200 0 200 0 200 100 <th></th> <th>unen nebi</th> <th>ost account, the Direct</th> <th>n is nereby</th> <th>autorized to.</th> <th>(chock all ular a</th> <th>וניקק</th> <th>al a an</th>		unen nebi	ost account, the Direct	n is nereby	autorized to.	(chock all ular a	וניקק	al a an		
⊠ Charge any additional fee(s) or underpayments of fee(s) ⊠ Credit any overpayments WARNING: Information and authorization on PTO-2038. FEE CALCULATION FEE CALCULATION Small Entity Small Entity Small Entity Small Entity Application Type Fee (s) Fee(s) <	Charge fee	s) indicate	d below		Cha	rge fee(s) indical	ted below, excep	t for the filing		
La Standard Strike Standard Strike Strike Standard Strike Stri	Charge any	additional	fee(s) or undernavmen	ts of feels		dit anv overnavm	ents			
WARNING: Information of bit form may be form apy belic. Credit card information and autorization on PT02838. FEE CALCULATION Information and autorization on PT02838. FEE CALCULATION SEARCH FEES EXAMINATION FEES FLING FEES SEARCH FEES EXAMINATION FEES Design SearCH FEES EXAMINATION FEES Design Col 100 SizeOCH FEES EXAMINATION FEES Design ZO0 100 SizeOCH FEES EXAMINATION FEES Design ZO0 100 SizeOCH FEES ExaClaim SizeOCH Esc (S) Fee(S) Fee(S) <t< th=""><th>Linder 37 C</th><th>ER 1 16 -</th><th>nd 1 17</th><th>ins of iee(S</th><th></th><th>ar any overpayin</th><th>icina</th><th></th></t<>	Linder 37 C	ER 1 16 -	nd 1 17	ins of iee(S		ar any overpayin	icina			
Information and authorization on PTO-2038. FEE CALCULATION I. BASIC FILING, SEARCH, AND EXAMINATION FEES FILING FEES SEARCH FEES EXAMINATION FEES Application Type Fee (\$) Fee(\$) Fee (\$) Fee (\$) <th colsp<="" td=""><td>WARNING: Information on this</td><td>form may</td><td>become public. Credit ca</td><td>rd informat</td><td>ion should not h</td><td>e included on the</td><td>s form, Provide cr</td><td>edit card</td></th>	<td>WARNING: Information on this</td> <td>form may</td> <td>become public. Credit ca</td> <td>rd informat</td> <td>ion should not h</td> <td>e included on the</td> <td>s form, Provide cr</td> <td>edit card</td>	WARNING: Information on this	form may	become public. Credit ca	rd informat	ion should not h	e included on the	s form, Provide cr	edit card	
FEE CALCULATION 1. BASIC FILING, SEARCH, AND EXAMINATION FEES FILING FEES SEARCH FEES Small Entity Small Entity Small Entity Small Entity Application Type Fee (\$) Fee (\$) <t< th=""><th>information and authorization of</th><th>on PTO-20:</th><th>38.</th><th>o national</th><th>Non should not .</th><th></th><th>e terme i rende et</th><th></th></t<>	information and authorization of	on PTO-20:	38.	o national	Non should not .		e terme i rende et			
Fee CALCULATION 1. BASIC FILING, SEARCH, AND EXAMINATION FEES FILING FEES SEARCH FEES Small Entity EXAMINATION FEES Small Entity Small Entity see(\$) Eee(\$) Fee(\$)	FEE CALCULATION	1000 1000 1000								
1. BASIC FILING, SEARCH, AND EXAMINATION FEES FILING FEES FILING FEES FILING FEES Small Entity SEARCH FEES SearCH FEES SearCH FEES Fee(\$) EXAMINATION FEES Fee(\$) Small Entity Fee(\$) Small Entity Fee(\$) Small Entity Fee(\$) Small Entity Fee(\$) Fees Paid Fees Paid Fees Paid Utility 300 150 500 250 200 100 \$1,000,01 Design 200 100 300 150 50 250 200 100 \$1,000,01 Plant 200 100 300 150 100 80	FEE CALCOLATION									
FILING FEES SEARCH FEES EXAMINATION FEES Application Type Fee (5) Fee	1. BASIC FILING, SEAF	CH, AN	D EXAMINATION FE	ES						
Small EntitySmall EntitySmall EntitySmall EntitySmall EntityFee(\$)Fee(FILING I	FEES	SEARCH	FEES	EXAMIN	NATION FEES			
Application Type Fee (\$)			Small Entity	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	Small Entit	tv	Small Entity			
Definition (1) Definition Definit <thdefinition< th=""> Definit</thdefinition<>	Application Type	Fee (S)	Fee(\$)	Fee(\$)	Fee(\$)	Fee(\$)	Fee(\$)	Fees Paid		
Other Statuture Statuture Statuture Statuture Statuture Design 200 100 100 50 130 65	Application Type	100 101	150	FOO	260	100101	100	£1 000 00		
Design 200 100 100 50 130 65	Utility	300	120	500	250	200	100	21,000.00		
Plant 200 100 300 150 160 80	Design	200	100	100	50	130	65			
Reissue 300 150 500 250 600 300	Plant	200	100	300	150	160	80	- Cardon 1		
Provisional 200 100 0 0 0 0 2. EXCESS CLAIM FEES Small Entity Fee Obscription Small Entity Fee (\$)	Reissue	300	150	500	250	600	300			
Protocolation Dot	Provisional	200	100	0	0	0	0			
2. EXCESS CLAIM FEES Small Entity Fee Description Fee (\$)			100	U	v	U	v			
Fee Description Fee (\$) Fee (\$) <th <<="" colspan="2" td=""><td>2. EXCESS CLAIM FEE</td><td>5</td><td></td><td></td><td></td><td></td><td>and the second</td><td>Small Entity</td></th>	<td>2. EXCESS CLAIM FEE</td> <td>5</td> <td></td> <td></td> <td></td> <td></td> <td>and the second</td> <td>Small Entity</td>		2. EXCESS CLAIM FEE	5					and the second	Small Entity
Each claim over 20 (including Reissues) 50 25 Each independent claim over 3 (including Reissues) 360 180 Multiple dependent claims 360 180 Multiple Dependent claims Fee(\$) Fee Paid (\$) Multiple Dependent (\$) 02 -20 or HP= 00 x = Fee (\$) Fee (\$) HP = highest number of total claims paid for, if greater than 20. Fee (\$) Fee (\$) Fee (\$) Fee (\$) HP = highest number of independent claims paid for, if greater than 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 shcets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 shcets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Fee Paid (\$) Fee Paid (\$) Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$) Non-English Specification, \$130 fee (no small entity discount)	Fee Description						Fee (\$)	Fee (\$)		
Each independent claim over 3 (including Reissues) 200 100 Multiple dependent claims Extra Claims Fee(\$) Fee Paid (\$) Multiple Dependent claims Extra Claims Fee(\$) Fee Paid (\$) Multiple Dependent claims Fee(\$) Fee (\$) Fee (\$) HP = highest number of total claims paid for, if greater than 20.	Each claim over 20 (inclu	ding Reis	isues)				50	25		
Multiple dependent claims 360 180 Total Claims Extra Claims Fee(\$) Fee Paid (\$) Multiple Dependent (\$) 02 -20 or HP= 00 x	Each independent claim of	over 3 (inc	luding Reissues)				200	100		
Total Claims Extra Claims Fee(\$) Fee Paid (\$) Multiple Dependent (\$) 02 -20 or HP= 00 x =	Multiple dependent claim	IS			5.65.00		360	180		
02 -20 or HP= 00 x = Fee [\$) Fee [\$] HP = highest number of total claims paid for, if greater than 20. Indep. Claims Extra Claims Fee(\$) Fee [\$] 01 -03 or HP= 00 x =	Total Claims	Extra C	laims Fee(\$)	Fee	e Paid (\$)		Multiple	Dependent (
HP = highest number of total claims paid for, if greater than 20.	02 - 20 or HP=	00	x	-			Fee (\$) Fee F		
Indep. Claims Extra Claims Fee(\$) Fee Paid (\$) 01 -03 or HP= 00 x = HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee Paid (\$	HP = biohest ourshar of fai	al claime ar	aid for if greater than 20	100						
Indep. Claims EXtra Claims Fee[5] Fee Paid [5] 01 -03 or HP= 00 x =	nr - nignest number of tot	Ereter Clarins pa	no ior, it greater than 20.	-	Date (b)					
01 -03 or HP= 00 x = HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$	Indep. Claims	Extra C	laims Fee(\$)	Fee	e Paid (\$)					
HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). <u>Total Sheets</u> Extra Sheets <u></u>	01 -03 or HP=	00	x	문 그						
3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$	HP = highest number of inc	dependent of	alaims paid for, if greater th	an 3.						
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$) Total Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$) — (round up to a whole number) x — Gubmittee (e.g., late filing surcharge): Other (e.g., late filing surcharge): SUBMITTED BY Name (PrintType) Doreen Yatko Trujilio	3. APPLICATION SIZE E	EE	and the second second second							
In the operation and on average root sites of paper (containing electronically fried sequence of computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Interview of fraction thereof. See 35 U.S.C. 41(a)(1)(G) and an one of the sequence of the seque	If the specification and dra	wings ave	eed 100 sheets of some	r (excludia	a electronical	ly filed commence	or computer			
sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Fee Paid (\$	listing under 17 C	FR 1 500	a)) the application size	fee dua in	\$750 (\$175 F	remail antitul fo	ar each additions	1 50		
Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$	sheets or fraction t	hereof C	a 3511 S.C. Allaving	and 17 C	FR 16(-)	a sman citity) it	a cach auditiona			
Interior of each additional so of fraction thereof ree (s) Fee Paid (s)	Total Shoate	Evtra CL	ente Number of	pach ad	ditional 50 a	fraction there	of Eas (t)	Fee Daid /		
	Total offeets	LAUA ON	number of	cacil add	altional 50 Of	nacion there	Tee lei	ree Paid (\$		
4. OTHER FEE(S) Fees Paid (Non-English Specification, \$130 fee (no small entity discount)			=	(round up	to a whole n	umber) x				
Non-English Specification, \$130 fee (no small entity discount)	4. OTHER FEE(S)							Fees Paid (
Other (c.g., late filing surcharge):	Non-English Speci	fication 9	130 fee (no small entit	v discount	0					
SUBMITTED BY Signature Addled Mathematical Action No. 35,719 Telephone (215) 6 Name (Print/Type) Doreen Yatko Trujilio Date Noven	Other (a - lose Cit	ing much	ingo) :	, and out						
SUBMITTED BY Signature Addled	Other (e.g., late fill	ing surcha	uge):							
SUBMITTED BY Registration No. 35,719 Telephone (215) 6 Signature Doreen Yatko Trujilio Doreen Yatko Trujilio Date Noven				-						
Signature Name (Print/Type) Doreen Yatko Trujilio Automatical (Attomes/Agent) 35,719 Telephone (215) 6 Name (Print/Type) Doreen Yatko Trujilio Date Noven	SUBMITTED BY	1.1 ····	11.0-1	An	Pagistration No.					
Name (Print/Type) Doreen Yatko Trujilio // Date Noven	Signature	rees	1 yathook	inl	(Attomey/Agent)	35,719	Telephone	e (215) 6		
	100		11							

112105

DOCKET

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

BEST AVAILABLE COPY PCT/GB90/02017

HUMANISED ANTIBODIES

Field of the Invention

The present invention relates to humanised antibody molecules, to processes for their production using recombinant DNA technology, and to their therapeutic uses.

The term "humanised antibody molecule" is used to describe a molecule having an antigen binding site derived from an immunoglobulin from a non-human species, and remaining immunoglobulin-derived parts of the molecule being derived from a human immunoglobulin. The antigen binding site typically comprises complementarity determining regions (CDRs) which determine the binding specificity of the antibody molecule and which are carried on appropriate framework regions in the variable domains. There are 3 CDRs (CDR1, CDR2 and CDR3) in each of the heavy and light chain variable domains.

In the description, reference is made to a number of publications by number. The publications are listed in numerical order at the end of the description.

Background of the Invention

Natural immunoglobulins have been known for many years, as have the various fragments thereof, such as the Fab, (Fab')2 and Fc fragments, which can be derived by enzymatic cleavage. Natural immunoglobulins comprise a generally Y-shaped molecule having an antigen-binding site towards the end of each upper arm. The remainder of the structure, and particularly the stem of the Y, mediates the effector functions associated with immunoglobulins.

Natural immunoglobuling have been used in assay, diagnosis and, to a more limited extent, therapy. However, such uses, especially in therapy, were hindered until recently by the polyclonal nature of natural immunoglobulins. A significant step towards the realisation of the potential

of immunoglobuling as therapeutic agents was the discovery of procedures for the production of monoclonal antibodies (MAbs) of defined specificity (1).

However, most MAbs are produced by hybridomas which are fusions of rodent spleen cells with rodent myeloma cells. They are therefore essentially rodent proteins. There are very few reports of the production of human MAbs.

Since most available MAbs are of rodent origin, they are naturally antigenic in humans and thus can give rise to an undesirable immune response termed the HAMA (Human Anti-Mouse Antibody) response. Therefore, the use of rodent MAbs as therapeutic agents in humans is inherently limited by the fact that the human subject will mount an immunological response to the MAb and will either remove it entirely or at least reduce its effectiveness. In practice, MAbs of rodent origin may not be used in patients for more than one or a few treatments as a HAMA response soon develops rendering the MAb ineffective as well as giving rise to undesirable reactions. For instance, OKT3 a mouse IgG2a/k MAb which recognises an antigen in the T-cell receptor-CD3 complex has been approved for use in many countries throughout the world as an immunosuppressant in the treatment of acute allograft rejection (Chatenoud et al (2) and Jeffers et al (3)1. However, in view of the rodent nature of this and other such MAbs, a significant HAMA response which may include a major anti-idiotype component, may build up on Clearly, it would be highly desirable to diminish use. or abolish this undesirable HAMA response and thus enlarge the areas of use of these very useful antibodies.

Proposals have therefore been made to render non-human MAbs less antigenic in humans. Such techniques can be generically termed "humanisation" techniques. These

techniques typically involve the use of recombinant DNA technology to manipulate DNA sequences encoding the polypeptide chains of the antibody molecule.

Early methods for humanising MAbs involved production of chimeric antibodies in which an antigen binding site comprising the complete variable domains of one antibody is linked to constant domains derived from another Methods for carrying out such chimerisation antibody. procedures are described in EP0120694 (Celltech Limited), EP0125023 (Genentech Inc. and City of Hope), EP-A-0 171496 (Res. Dev. Corp. Japan), EP-A-0 173 494 (Stanford University), and WO 86/01533 (Celltech Limited). This latter Celltech application (WO 86/01533) discloses a process for preparing an antibody molecule having the variable domains from a mouse MAb and the constant domains from a human immunoglobulin. Such humanised chimeric antibodies, however, still contain a significant proportion of non-human amino acid sequence, i.e. the complete non-human variable domains, and thus may still elicit some HAMA response, particularly if administered over a prolonged period [Begent et al (ref. 4)].

In an alternative approach, described in EP-A-0239400 (Winter), the complementarity determining regions (CDRs) of a mouse MAb have been grafted onto the framework regions of the variable domains of a human immunoglobulin by site directed mutagenesis using long oligonucleotides. The present invention relates to humanised antibody molecules prepared according to this alternative approach, i.e. CDR-grafted humanised antibody molecules. Such CDR-grafted humanised antibodies are much less likely to give rise to a HAMA response than humanised chimeric antibodies in view of the much lower proportion of non-human amino acid sequence which they contain. -

DOCKET

PCT/GB90/02017

The earliest work on humanising MAbs by CDR-grafting was carried out on MAbs recognising synthetic antigens, such as the NP or NIP antigens. However, examples in which a mouse MAb recognising lysozyme and a rat MAb recognising an antigen on human T-cells were humanised by CDR-grafting have been described by Verhoeyen <u>et al</u> (5) and Riechmann <u>et al</u> (6) respectively. The preparation of CDR-grafted antibody to the antigen on human T cells is also described in WO 89/07452 (Medical Research Council).

In Riechmann et al/Medical Research Council it was found that transfer of the CDR regions alone [as defined by Kabat refs. (7) and (8)] was not sufficient to provide satisfactory antigen binding activity in the CDR-grafted Riechmann et al found that it was necessary to product. convert a serine residue at position 27 of the human sequence to the corresponding rat phenylalanine residue to obtain a CDR-grafted product having improved antigen This residue at position 27 of the binding activity. heavy chain is within the structural loop adjacent to A further construct which additionally contained a CDR1. human serine to rat tyrosine change at position 30 of the heavy chain did not have a significantly altered binding activity over the humanised antibody with the serine to phenylalanine change at position 27 alone. These results indicate that changes to residues of the human sequence outside the CDR regions, in particular in the structural loop adjacent to CDR1, may be necessary to obtain effective antigen binding activity for CDR-grafted antibodies which recognise more complex antigens. Even so the binding affinity of the best CDR-grafted antibodies obtained was still significantly less than the original MAb.

Very recently Queen et al (9) have described the preparation of a humanised antibody that binds to the

LARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

